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Abstract
Rationale Pathological impulsivity is a prominent feature
in several psychiatric disorders, but detailed understanding
of the specific neuronal processes underlying impulsive
behavior is as yet lacking.
Objectives As recent findings have suggested involvement
of the brain cannabinoid system in impulsivity, the present
study aimed at further elucidating the role of cannabinoid
CB1 receptor activation in distinct measures of impulsive
behavior.
Materials and methods The effects of the selective canna-
binoid CB1 receptor antagonist, rimonabant (SR141716A) and
agonist WIN55,212-2 were tested in various measures of
impulsive behavior, namely, inhibitory control in a five-
choice serial reaction time task (5-CSRTT), impulsive choice
in a delayed reward paradigm, and response inhibition in a
stop-signal paradigm.
Results In the 5-CSRTT, SR141716A dose-dependently
improved inhibitory control by decreasing the number of
premature responses. Furthermore, SR141716A slightly
improved attentional function, increased correct response
latency, but did not affect other parameters. The CB1 receptor
agonist WIN55,212-2 did not change inhibitory control in
the 5-CSRTT and only increased response latencies and
errors of omissions. Coadministration of WIN55,212-2
prevented the effects of SR141716A on inhibitory control
in the 5-CSRTT. Impulsive choice and response inhibition
were not affected by SR141716A at any dose, whereas
WIN55,212-2 slightly impaired response inhibition but did
not change impulsive choice.
Conclusions The present data suggest that particularly the
endocannabinoid system seems involved in some measures
of impulsivity and provides further evidence for the existence
of distinct forms of impulsivity that can be pharmacologically
dissociated.
Keywords Cannabinoid . Cognition . Inhibitory control .
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WIN55,212-2
Introduction
Despite its relative recent discovery, the central endocan-
nabinoid system has been implicated in a variety of
behaviors such as food intake (for review, see Di Marzo
and Matias 2005) and nociception (for review, see Cravatt
and Lichtman 2004), and in mediating the reinforcing
properties of drugs of abuse (for review, see De Vries and
Schoffelmeer 2005). In addition, the endocannabinoid
system has been shown to play an important role in various
cognitive processes. In this respect, memory encoding,
retrieval, and extinction processes have received most
interest (e.g., Marsicano et al. 2002; Takahashi et al.
2005; Varvel et al. 2005; for review, see Lichtman et al.
2002), presumably due to the high expression level of CB1
receptors in the hippocampal formation (Egertova and
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Elphick 2000; Tsou et al. 1998). High densities of CB1
receptors are also present in frontal cortical and striatal
regions (Egertova and Elphick 2000; Tsou et al. 1998),
suggesting involvement of the endocannabinoid system in
executive functions that appear to be largely controlled by
frontal corticostriatal systems (for review, see Miller and
Cohen 2001). Indeed, several clinical and preclinical
observations have demonstrated that Δ9-tetrahydrocan-
nabinol (THC), the principle active cannabinoid of
Cannabis sativa and other synthetic cannabimimetics
impair selective attention (Arguello and Jentsch 2004;
Solowij et al. 1995; Verrico et al. 2004) and behavioral
flexibility (Egerton et al. 2005; Hill et al. 2006), alter time
estimation (Han and Robinson 2001, McDonald et al.
2003), and impair working memory (Ilan et al. 2004;
Jentsch et al. 1997). Nonetheless, to date, little is known
about the involvement of the endocannabinoid system in
other executive functions such as inhibitory control
processes subserving impulsivity.
Pathological levels of impulsive behavior are important
features in attention-deficit/hyperactivity disorder, sub-
stance-related disorders, bipolar disorders and personality
disorders (American Psychiatric Association 2000). Further
elucidating the neurobiological basis of impulsivity may
therefore enhance our understanding of these psychiatric
disorders. It is becoming increasingly clear, however, that
the concept impulsivity is multifaceted and covers various
distinct and independent measures. These measures range
from poor inhibitory control (impulsive action) to proba-
bility and delay aversion or impulsive choice (Barkley
1997; Evenden 1999; Moeller et al. 2001). Recent studies
have implicated CB1 receptors in some of these measures of
impulsivity. For instance, it has been shown that acute THC
impairs response inhibition in healthy volunteers, whereas
time estimation and impulsive choice were not affected
(McDonald et al. 2003). On the other hand, it has been
demonstrated more recently that marijuana acutely increases
risk taking in volunteers (Lane et al. 2005). Collectively,
these data suggest a role of the cannabinoid system in
impulsivity, although its precise role therein is still unclear.
The present experiments were aimed at further elucidat-
ing the importance of cannabinoid CB1 receptor activation
on distinct measures of impulsivity. To this end, we tested
the effects of the potent and selective CB1 receptor
antagonist rimonabant (SR141716A; Rinaldi-Carmona et al.
1994) and agonist WIN55,212-2 (D’Ambra et al. 1992) on
impulsive behavior in various operant paradigms measuring
different and presumably independent aspects of impulsivity
(for review, see Winstanley et al. 2006), namely, (1) the five-
choice serial reaction time task to measure inhibitory control;
(2) the delayed reward paradigm to measure impulsive
choice, and (3) the stop-signal paradigm to measure response
inhibition.
Materials and methods
Subjects
In total, 48 male Wistar rats were obtained from Harlan
CPB (Horst, The Netherlands). At the start of the experi-
ments, animals were 12 weeks old, weighed approximately
250 g, and were housed in pairs in macrolon cages (42.5×
26.6×18.5 cm; l×w×h) under a reversed 12 h light/dark
cycle (lights on at 7:00 P.M.) at controlled room temperature
(21±2°C) and relative humidity of 60±15%. Animals
were maintained at approximately 90% of their free-feeding
weight, starting 1 week before the beginning of the
experiments by restricting the amount of standard rodent
food pellets (Harlan Teklad Global Diet, Blackthorn, UK).
Water was available ad libitum throughout the entire
experiment. All experiments were conducted with the
approval of the animal ethical committee of the Vrije
Universiteit, Amsterdam, The Netherlands.
Apparatus
Experiments were conducted in 12 identical rat five-hole
nose poke operant chambers with stainless steel grid floors
(MED-NPW-5L, Med Associates, St. Albans, VT, USA)
housed in sound-insulating and ventilated cubicles. Set in
the curved wall of each box was an array of five circular
holes, 2.54 cm in diameter, 2.2 cm deep, and 2.25 cm above
floor level. Each hole was equipped with an infrared
detector located across each nose poke unit 1.0 cm from
the front, and a yellow LED stimulus light (6.4 mm in
diameter). Rodent food pellets (45 mg, Formula P,
Research Diets, New Brunswick, NJ, USA) could be
delivered at the opposite wall via a dispenser. In addition,
the chamber could be illuminated by a white houselight,
and sound stimuli were generated using a programmable
audio generator (ANL-926, Med Associates). A computer
equipped with MED-PC version 1.17 (Med Associates)
controlled experimental sessions and recorded data. Ani-
mals were tested once daily from Monday until Friday,
during the dark phase of the light/dark cycle.
Behavioral procedures
Separate groups of n=16 animals were trained for each
different paradigm, and for all procedures, a similar
habituation and magazine training protocol was used. This
protocol consisted of a habituation exposure to the boxes for
20 min with the houselight on and the food cup containing
three food pellets for two consecutive sessions. Subsequent-
ly, in the next two sessions, in total, 100 pellets were
delivered with an average delay of 15 s, to allow the animals
to associate the sound of pellet delivery with reward.
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Five-choice serial reaction time task
A more detailed description of training in the 5-CSRTT in
our laboratory has been reported previously (Van Gaalen et
al. 2006a). In short, rats were trained 5 days per week to
detect and respond to a brief visual stimulus in one of five
holes to obtain a food reward. Each session terminated after
100 trials or 30 min, whichever occurred first. Initially the
duration of this stimulus was 32 s and was gradually
decreased to 1 s over sessions until animals reached stable
baseline performance (accuracy >80% correct choice and
<20% errors of omission). Responding during stimulus
presentation or within the limited hold (LH) period of 2 s
was counted as a correct response. Incorrect, premature
responses and errors of omission (no responses or a
response after the LH) did not lead to the delivery of a
food reward and resulted in a 5-s time-out period during
which the houselight was extinguished, whereas persever-
ative responses, i.e., repeated responding during the
presentation of the stimulus, were measured but did not
have any programmed consequences. Two different mea-
sures of inhibitory control were measured, namely, (1) the
number of premature responses before the onset of the
visual stimulus, reflecting aspects of loss of inhibitory
control and (2) the number of perseverative responses into
the stimulus hole after correct choice, presumably measur-
ing aspects of compulsive behavior. In addition, the
following other behavioral parameters were measured that
reflect task performance, namely, (3) accurate choice, i.e.,
percentage correct responses calculated as [number correct
trials/(correct+incorrect trials)]×100; (4) latency to make a
correct choice, i.e., the mean time between stimulus onset
and nose poke in the illuminated hole; (5) omission errors,
i.e., the number of omitted trials during a session; and (6)
feeder latency, i.e., the latency to collect a pellet following
correct choice.
Delayed-reward paradigm
In addition to the 5-CSRTT, the delayed reward paradigm,
as employed in our laboratory, has also been described
more elaborately (Van Gaalen et al. 2006b). Briefly, rats
were trained 5 days per week in this paradigm. In the final
stages of training and during drug testing, a session was
divided into 5 blocks of 12 trials, each block starting with 2
forced trials during which, after initiating the trial through a
nose poke into the central hole, either the left hole or the
right hole was illuminated in a counterbalanced fashion. In
the next ten trials, the animals had a free choice, and both
the left and right hole were illuminated. Poking into one
position resulted in the immediate delivery of a small
reinforcer (one food pellet), whereas a nose poke into the
other position resulted in the delivery of a large, but
delayed, reinforcer (four food pellets). If an animal did not
make a response during this choice phase within 10 s, an
intertrial interval was initiated, and the trial was counted as
an omission. The position associated with the small and
large reinforcer was always the same for each individual
and counterbalanced for the group. The delay for the large
reinforcer progressively increased within a session per
block of 12 trials as follows: 0, 10, 20, 40, and 60 s.
Responding into non-illuminated holes during the test was
recorded, but had no programmed consequences. The
behavioral measure to assess task performance, i.e., the
percentage preference for the large reinforcer as a function
of delay, was calculated as: the number of choices for the
large reinforcer / (number choices large+small rein-
forcers)×100. In addition, we calculated the total number
of omitted choice trials within a session.
Stop-signal paradigm
Shaping During initial shaping for two consecutive ses-
sions, both the middle nose poke hole and the hole
immediately adjacent to the right or left were illuminated
(counterbalanced for all subjects). A nose poke into either
one of the two active holes extinguished the visual stimuli
in both holes and resulted in delivery of a pellet. After an
intertrial interval of 10 s, the next trial started. Nose poking
within this intertrial interval period did not have any
programmed consequences. A session ended when the rat
had earned 100 pellets or after 30 min, whichever occurred
first.
Shaping: go trials During the next phase, only the stimulus
light in the middle nose poke hole was illuminated (start
stimulus). A response into the active middle hole switched
off the stimulus light and was followed by the illumination
of the stimulus light (go stimulus) in the hole immediately
adjacent to the left or right. A nose poke into this
illuminated hole switched off the stimulus light and resulted
in the delivery of a pellet. After an intertrial interval of 10 s,
the next trial started. Responding in the start stimulus hole
during presentation of the go stimulus was counted as
perseverative start pokes, whereas prestimulus responses
into the go stimulus hole resulted in a timeout period of 5 s.
Subsequently, the response requirements into the start
stimulus hole before onset of a go stimulus were varied
into a variable ratio 2 schedule (VR2, i.e., either FR1, FR2,
or FR3) to avoid the development of a prepotent response
pattern from start stimulus to go stimulus hole and to ensure
that animals waited until the appearance of a go stimulus.
During this phase, rats were trained until they reliably
completed 200 successful go trials. Following this phase, a
LH period was introduced for the go stimulus and only
during this period was the go stimulus present. Initially, the
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LH was set at 5 s, and in subsequent sessions, was
individually titrated to meet performance criterion of 80%
successful hits and <20% prestimulus responses. Omissions
of a go stimulus response within the LH resulted in a 5-s time-
out period, during which both the houselight and stimulus
light were turned off. From initial shaping to criterion
performance in this phase, 26 sessions were required.
Shaping: introduction stop signal During the final training
phase, a stop signal was introduced in 25% of all trials.
Initially, this stop signal (duration, 50 ms; frequency,
4,500 Hz; intensity 80 dB) was contingent with the
appearance of the go signal. Responding during the onset
of the stop signal or during the LH immediately extin-
guished the go stimulus and houselight, turned off the stop
signal, and was followed by a 5-s time-out. In contrast, if
the animal successfully refrained from responding during a
stop trial, a pellet was delivered. Initially, the LH during
stop and go trials were equal; however, when performance
during stop trials was below 80% successfully inhibited
stop trials, the LH during stop trials was lowered over
sessions in steps of 100–200 ms until animals improved
performance. Subsequently, the LH was then gradually
increased in these individuals over sessions until the LH
during both go and stop trials were equal. As soon as
animals reached the criterion of approximately 90%
successfully inhibited stop trials, delays for the onset of
the stop signal were introduced. The stop-signal delays
(SSD) were presented in a pseudorandom order, and to
compensate for differences between rats, SSDs were based
on each individual rats’ mean reaction time on go trials in
the preceding drug-free training session. SSDs were
calculated as follows: mRT minus either 25, 50, 100, 200,
or 400 ms. In addition, an equal amount of zero delays were
presented during sessions. Drug testing commenced upon
stable baseline performance for at least five consecutive
sessions, i.e., 80% accuracy during go trials and a
significant SSD-dependent decrease in correctly inhibited
stop trials. It took 30 sessions before animals reached stable
baseline performance after the introduction of the stop
signal; therefore, from initial shaping to stable baseline
performance in the stop-signal paradigm, in total, 56 sessions
were required.
Stop-signal paradigm: estimation stop-signal reaction time
and correction for omissions during go trials
Calculations to estimate the stop-signal reaction times
(SSRT) and a correction for omission errors were adapted
from Logan (1994) and Solanto et al. (2001). For
estimating the SSRT, data of the three SSDs of 200, 100,
and 50 ms were used, as the probability of correct
inhibition on these intervals was within the range of 0.2<
p<0.8, and thus, most informative for estimating SSRT
(Band et al. 2003). For each of the three intervals, the
probability of responding was calculated including a
correction for nonresponses based on the number of
omissions during the go trials, the latter, as omissions
cannot be distinguished from successful inhibitions during
stop trials. The following formula, adapted from Solanto et
al. (2001) was used for these calculations:
p respondingð Þ ¼ x correct inhibitionsð Þ=x xyj j;
where x is the number of stop-signal trials at each delay
interval; correct inhibitions are the number of correctly
inhibited trials, and y is the probability of omissions
during the go trials within the entire session. To calculate
SSRTs, reaction times on all go trials were rank ordered.
From this list with RTs, the “nth” RT was taken, where “n“
was obtained by multiplying the total number of go trials
by the probability of responding for a particular SSD. This
RT value approximates the latency between onset of the
go stimulus and completion of the stopping process. The
SSRT for each interval is then obtained by subtracting
the SSD interval from this RT. The average estimated
SSRT that is used for the analyses in the present study is
calculated by taking the mean of each SSRT at the three
SSDs (200, 100, and 50 ms).
Drugs
SR141716A was generated and kindly donated by Solvay
Pharmaceuticals (Weesp, The Netherlands), whereas
WIN55,212-2 was purchased from Tocris Biosciences
(Bristol, United Kingdom). Both SR141716A and
WIN55,212-2 were dissolved as described previously in a
mixture of ethanol, Tween80, and sterile saline (ratio
1:1:18; cf. De Vries et al. 2001). In all experiments,
SR141716A was injected 30 min before testing, whereas
WIN55,212-2 was injected 20 min before testing. In all
paradigms, the order of testing the drugs was (1)
SR141716A and (2) WIN55,212-2. The drug combination
was only performed in the five-choice serial reaction time
task and followed the studies with SR141716A and
WIN55,212-2. Drugs were freshly prepared each day
before testing and intraperitoneally injected in a volume
of 1 ml/kg bodyweight according to a Latin square design
for both the dose–response studies and the drug combina-
tion on Tuesdays and Fridays, with baseline training
sessions on the other weekdays.
Statistical analyses
Data were subjected to repeated measures analysis of
variance (ANOVA) with drug dose (all paradigms), delay
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to large reinforcer (delayed reward paradigm), and stop-
signal delay (stop-signal paradigm) as within subjects
variables using the Statistical Package for the Social
Sciences version 11 (SPSS, Chicago, IL, USA).
The homogeneity of variance across groups was deter-
mined using Mauchly’s tests for equal variances, and in case
of violation of homogeneity, corrected, and therefore, more
conservative Huynh–Feldt probability values were used for
subsequent analyses. In the stop-signal paradigm, some
further exploratory analyses were performed between mean
go reaction times and the limited hold period using a bivariate
Pearson correlation. In addition, the estimated SSRT data
were also subjected to a median split analysis to assess
whether SR141716A or WIN55,212-2 had differential effects
on response inhibition in individuals with relatively “fast” or
“slow” stopping abilities. In case of statistically significant
main effects, further post hoc comparisons were conducted
using Student–Newman–Keuls Tests. The level of probability
for statistically significant effects was set at 0.05.
Results
Effects of SR141716A and WIN55,212-2 on measures
of inhibitory response control in the five-choice serial
reaction time task
The number of premature responses, a measure of inhibi-
tory control reflecting impulsive behavior, was dose
dependently decreased by SR141716A [Fig. 1a; F3,45=
12.24, p<0.001], and further post hoc analyses revealed
that all doses significantly lowered premature responding
compared with vehicle, whereas the highest dose (3.0 mg/kg)
even further lowered the number of premature responses
compared with 1.0 mg/kg SR141716A. In contrast, persev-
erative responding after correct choice, a different measure of
inhibitory control reflecting compulsive behavior, was not
affected at any dose [Fig. 1b; F3,45=1.84, p=0.15]. Atten-
tional function was improved by SR141716A, and further
analyses revealed that only 0.3 mg/kg SR141716A signifi-
Fig. 1 Effects of SR141716A
(a, b) and WIN55,212-2 (c, d)
on different measures of inhibi-
tory control in the 5-CSRTT.
Data depict mean (±SEM)
numbers of premature responses
(a, c) and perseverative
responses after correct choice
(b, d). *p<0.05 and **p<0.005
vs vehicle
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cantly increased the percentageof accurate choice from ap-
proximately 77% under vehicle conditions to 82% as shown
in Table 1 [F3,45=3.43, p=0.025]. In addition, a marginal, but
significant, increase in the latency to make a correct choice
was also detected, and further comparisons showed that only
the high dose of 3.0 mg/kg significantly slowed correct re-
sponse reaction time [Table 1; F3,45=4.53, p=0.007]. The la-
tency to collect a food reward and errors of omission, however,
were not affected at any dose [Table 1; feeder latency: F3,45=
0.39, p=0.65 and omissions: F3,45=1.30, p=0.29].
WIN55,212-2 did neither change the number of prema-
ture responses nor the number of perseverative responses
after correct choice [Fig. 1c and d; premature responses:
F3,45=1.02, p=0.39 and perseverative responses: F3,45=
1.64, p=0.21; respectively]. Furthermore, as indicated in
Table 1, WIN55,212-2 did not change accurate choice or
the latency to collect a pellet after correct choice [accurate
choice: F3,45=0.72, p=0.54 and feeder latency: F3,45=3.19,
p=0.052]. In contrast, errors of omission were increased,
and latencies to make a correct choice were lengthened by
WIN55,212-2 [omissions: F3,45=7.44, p=0.002 and correct
response latency: F3,45=6.59, p=0.004].
As shown in Fig. 2, the decrements in premature
responding by 3.0 mg/kg SR141716A were prevented in
the presence of WIN55,212-2 at a dose of 1.0 mg/kg [F3,45=
7.33, p<0.001]. In addition, this selected dose of
WIN55,212-2, by itself, did not affect inhibitory control
as indicated by the absence of an effect of this dose on the
number of premature responses.
SR141716A and WIN55,212-2 do not affect decision
making in the delayed reward paradigm
Stable baseline performance on the delayed reward paradigm
occurred after approximately 30 training sessions on a full
delay range (0, 10, 20, 40, and 60 s), and therefore, we
commenced drug testing from session 35 onwards. A clear,
highly significant delay-dependent decrement in the percent-
age preference for the large reinforcer was observed [Fig. 3;
delay: F4,60=270.22, p<0.001]. Nonetheless, SR141716A
did not shift the preference for a large reinforcer over delays
at any of the tested doses [dose: F3,45=1.56, p=0.21 and
dose ×delay: F12,180 = 1.24, p=0.29]. In addition,
SR141716A also did not change the total numbers of
omitted choice trials, i.e., the failures to start a trial during
the choice phase [dose: F3,45=3.10, p=0.052].
In the WIN55,212-2 experiments, at the highest dose, in
total, five animals omitted all choice trials of some delays,
and therefore, were excluded from all analyses of the delay
discounting data. Similar to SR141716A, increasing the
delay highly significantly shifted the preference from large
to the small reinforcer [Fig. 4; delay: F4,40=179.06, p<
0.001]. Although there was no overall effect of
WIN55,212-2 on decision making [dose: F3,30=0.68, p=
0.57], there was a dose by delay interaction effect
suggesting a shift in preference for the large reinforcer
over delays [dose × delay: F12,120=2.61, p=0.011]. None-
theless, further post hoc comparisons revealed no differ-
ences between vehicle and any of the other doses. The
number of omitted choice trials was not affected by
WIN55,212-2 [dose: F3,30=1.61, p=0.21].
Effects of SR141716A and WIN55,212-2 on response
inhibition in the stop-signal paradigm
Under baseline conditions in the stop-signal paradigm,
there was stable individual variation in mean reaction times
during go trials over consecutive sessions ranging from 290
to 470 ms (mean: 365 ms; standard deviation: 58 ms).
Likewise, the limited hold periods during go and stop trials
also stably varied and ranged from 400 to 1,100 ms (mean:
594 ms; SD: 167 ms). A highly significant positive
correlation indicated that individuals with “shorter” limited
hold periods also displayed shorter mean go reaction times
compared to individuals with “longer” limited hold periods
that were slower in go reaction speed [r=0.85, p<0.001].
Response inhibition, as displayed in the inhibition
function curve in Fig. 4a, was not affected by SR141716A
Accuracy (%) Response latency (ms) Omissions (%) Feeder latency (ms)
SR141716A
Vehicle 77.2±2.4 336±9 5.4±1.1 954±48
0.3 mg/kg 82.0±1.9* 338±10 5.6±1.0 954±44
1.0 mg/kg 80.5±2.5 347±14 5.1±0.7 937±43
3.0 mg/kg 80.2±2.3 374±14* 7.3±1.0 939±37
WIN55,212-2
Vehicle 77.7±2.5 324±7 3.9±0.7 956±53
0.3 mg/kg 79.6±2.3 333±10 3.4±0.7 910±41
1.0 mg/kg 77.2±2.3 380±23* 14.4±4.3* 943±44
3.0 mg/kg 76.8±2.7 399±17** 20.2±4.1** 1212±138
Table 1 Effects of
SR141716A and WIN55,212-2
on measures of attentional
function and motivation in the
5-CSRTT. Data depict mean±
SEM
*p<0.05
**p<0.005 vs vehicle
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at any of the tested doses [dose: F3,45=1.28, p=0.29 and
dose×SSD: F12,180=1.25, p=0.26]; however, the percent-
age of correctly inhibited stop trials significantly declined
with decreasing stop-signal delays [SSD: F4,60=39.24, p<
0.001]. SR141716A did slow mean reaction times during
go trials by approximately 30 ms [Fig. 4b; dose: F3,45=
7.93, p=0.001], and further analyses indicated that both the
1.0 and 3.0 mg/kg dose significantly slowed reaction times
compared with vehicle. Nonetheless, the number of
omissions during go trials were not significantly affected
[mean±SEM: vehicle=16.2±3.0; 0.3 mg/kg=18.1±1.2;
1.0 mg/kg=17.7±1.7 and 3.0 mg/kg=23.3±2.6; dose:
F3,45=1.76, p=0.17]. Lastly, the average estimated SSRT
across three stop-signal delays, putatively reflecting re-
sponse inhibition, was not significantly changed by
SR141716A at any dose [Fig. 4c; dose: F3,45=1.47, p=
0.24]. Furthermore, a median split analysis (median SSRT:
238 ms) did not reveal differential effects of SR141716A
on the estimated SSRT in individuals with relatively “fast”
vs “slow” stopping abilities [slow vs fast stopper: F1,14=
9.54, p=0.008; dose: F3,42=1.04, p=0.38 and dose×slow
vs fast stopper: F3,42=2.48, p=0.074].
In the WIN55,212-2 experiments, at the highest dose, in
total, four animals did not start any go trials and were
therefore excluded from all stop-signal data analyses.
Response inhibition, as displayed in the inhibition function
curve in Fig. 5a, was affected by WIN55,212-2 [SSD: F4,44=
23.51, p<0.001; dose: F3,33=5.12, p=0.005 and dose×SSD:
F12,132=1.11, p=0.36], and further comparisons revealed
that 0.3 mg/kg WIN55,212-2 significantly deteriorated the
percentage of correct inhibition compared to vehicle. Mean
reaction times during go trials were slowed by WIN55,212-2
[Fig. 5b; dose: F3,33=15.07, p<0.001], and further analyses
indicated that 1.0 and 3.0 mg/kg WIN55,212-2 significantly
slowed mean reaction times compared to vehicle. Nonethe-
less, the number of omissions during go trials were not
significantly affected [mean±SEM: vehicle=14.8±1.9;
0.3 mg/kg=23.2±4.8; 1.0 mg/kg=26.1±5.4 and 3.0 mg/kg=
34.7±7.0; dose: F3,33=3.06, p=0.073]. Lastly, the average
estimated SSRT across three stop-signal delays, putatively
reflecting response inhibition, was not significantly changed
by WIN55,212-2 at any dose [Fig. 5c; dose: F3,33=2.06, p=
0.13]. Furthermore, a median split analysis (median SSRT:
227 ms) did not reveal differential effects of WIN55,212-2 on
the estimated SSRT in individuals with relatively “fast” vs
“slow” stopping abilities [slow vs fast stopper: F1,10=9.57, p=
0.011; dose: F3,30=2.12, p=0.12 and dose×slow vs fast
stopper: F3,30=1.30, p=0.29].
Fig. 3 Effects of SR141716A (a) and WIN55,212-2 (b) on the mean
(±SEM) percentage preference for the large reinforcer in the delayed
reward paradigm
Fig. 2 Coadministration of WIN55,212-2 at 1.0 mg/kg (WIN1)
prevents the effects of 3.0 mg/kg SR14716A (SR3) on inhibitory
control in the 5-CSRTT. All data are depicted as mean (±SEM). *p<
0.05 and **p<0.005
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Discussion
To our knowledge, this is the first report demonstrating
behavioral effects of a CB1 receptor agonist and antagonist
on independent measures of impulsivity. Thus far, evidence
pointing towards cannabinoid involvement in impulsivity
mainly originates from studies in which effects of THC or
marijuana were tested in human volunteers (Lane et al.
2005; McDonald et al. 2003). Our data obtained in the 5-
CSRTT strongly suggest that inhibitory control is modulat-
ed by an endogenous cannabinoid tone, as premature
responding was dose dependently decreased by
SR141716A. This notion is further supported by the
observation that in the presence of WIN55,212-2, the
effects of 3.0 mg/kg SR141716A on premature responding
were no longer observed. Furthermore, the finding that the
CB1 receptor agonist WIN55,212-2, by itself, did not
impair inhibitory control by increasing the number of
premature responses is in keeping with previous findings
(Arguello and Jentsch 2004). It should be noted though,
that in the study by Arguello and Jentsch (2004),
SR141716A (dose range: 0.1–1.0 mg/kg), by itself, did
not change premature responding in a lateralized reaction
time task, thereby, contrasting our findings. Nonetheless,
differences in baseline performance may have contributed
to the discrepancy in findings, as premature responding in
well-trained rats in the task by Arguello and Jentsch (2004)
was low (approximately 3 per session) compared to
premature responding in well-trained rats in the present
study (approximately 22 per session). Presumably, a floor
effect may have masked the effects of SR141716A on
premature responding in the lateralized reaction time task.
Together, our data indicate that performance in the 5-
CSRTT is associated with profound occupation of CB1
receptors by endogenously released cannabinoids. As might
then be expected, the endocannabinoid uptake inhibitor
AM404 did not affect inhibitory response control in the 5-
CSRTT (unpublished data). In contrast to premature
responding, perseverative responding after correct choice,
a different measure of inhibitory control that putatively
reflects compulsive behavior (Robbins 2002), was neither
altered upon activation nor blockade of CB1 receptors. This
Fig. 4 Effects of SR141716A
on response inhibition as mea-
sured in the stop-signal para-
digm. Data are depicted as mean
(±SEM) percentage of correctly
inhibited stop trials with varying
SSDs before the mean go RT
(a), go reaction times (b) and
estimated stop signal reaction
times from SSDs 200, 100, and
50 ms (c). **p<0.005 vs vehicle
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finding further underscores the dissociation between pre-
mature and perseverative responding in the 5-CSRTT that
has been shown to have a neuroanatomical basis as well
(Chudasama et al. 2003).
The endocannabinoid system interacts with many other
central neurotransmitters systems including the cholinergic,
GABAergic, glutamatergic, and opioid systems (Schlicker
and Kathmann 2001; Schoffelmeer et al. 2006). Moreover,
cannabimimetics have been shown to indirectly modulate the
release of dopamine and glutamate in corticostriatal regions
(e.g., Cheer et al. 2004; Szabo et al. 1999; Tanda et al. 1997;
Xi et al. 2006), most notably in the nucleus accumbens, and
particularly, these effects have been linked to the involve-
ment of the cannabinoid system in addiction (for review, see
De Vries and Schoffelmeer 2005). Although it is beyond the
scope of the present study and additional experiments are
required to substantiate this, one might speculate that the
present findings are explained by these modulatory effects of
the cannabinoid system on mesolimbic dopamine release, as
inhibitory control processes in the 5-CSRTT have been
shown to depend upon dopamine receptor activation within
the nucleus accumbens (Cole and Robbins 1987; Pattij et al.
2007). On the other hand, explanations for the beneficial
effects of SR141716A on inhibitory control may be due to
the role of the endocannabinoid system in feeding behavior
(for review, see Di Marzo and Matias 2005). Accordingly, it
has been demonstrated that SR141716A reduces intake of
normal and palatable food (e.g., Arnone et al. 1997;
Freedland et al. 2000; Thornton-Jones et al. 2005) and the
motivation to obtain food (Solinas and Goldberg 2005).
Nonetheless, despite these reported effects of SR141716A
on food intake, anorexic effects of this compound seem
unlikely to explain the current data, as both primary indices
of food-motivated behavior in the 5-CSRTT, namely, errors
of omission and feeder response latencies, were not changed.
It is interesting to note that we also observed a moderate
beneficial effect of SR141716A on visuospatial attention,
as it increased the level of accurate choice at 0.3 mg/kg.
Likewise, it has been shown that SR141716A improves
social recognition and spatial and aversive memory at
Fig. 5 Effects of WIN55,212-2
on response inhibition as mea-
sured in the stop-signal para-
digm. Data are depicted as mean
(±SEM) percentage of correctly
inhibited stop trials with varying
SSDs before the mean go reac-
tion times (a), go RTs (b) and
estimated stop signal reaction
times from SSDs 200, 100, and
50 ms (c). *p<0.05 and **p<
0.005 vs vehicle
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comparable dose ranges between 0.3 and 3.0 mg/kg
(Lichtman 2000; Takahashi et al. 2005; Terranova et al.
1996; Wolff and Leander 2003). Although the mechanisms
responsible for the beneficial effects of disrupting endo-
cannabinoid signaling on mnemonic and attentional pro-
cesses need to be elucidated further, it is interesting to note
that SR141716A increases, among others, cholinergic
neurotransmission in the medial prefrontal cortex in vivo
(Tzavara et al. 2003). This finding may be particularly
relevant for attentional function, as performance in the 5-
CSRTT has been shown to be accompanied by increments
in acetylcholine release in the medial prefrontal cortex
(Passetti et al. 2000), whereas decrements in acetylcholine
release in this brain region have been shown to correlate
with poor visuospatial attention (McGaughy et al. 2002).
A different measure of impulsivity we studied was
impulsive choice in the delayed reward paradigm. Concep-
tually, impulsive choice differs from inhibitory control in
the 5-CSRTT and rather reflects a cognitive decision-
making process, as rats have to weigh the immediate vs
delayed outcomes of their behavior. Impulsive choice then
is reflected in insensitivity towards the delayed larger
reward and a preference for the small immediate reward.
In the present experiments, we observed that neither
SR141716A nor WIN55,212-2 did have any effects on
impulsive choice. In accordance with these findings, it has
been shown recently that THC did not change delay and
probability discounting in human volunteers (McDonald et al.
2003), and together, these data suggest that the (endo)
cannabinoid system is not critically involved in impulsive
choice. Our observations do contrast with previous findings
indicating that marijuana elevates risk-taking behavior in
volunteers (Lane et al. 2005). Risk taking, however, differs
from delay and probability aversion in that it is most likely
to occur when the behavioral options may result in losses or
have aversive consequences (Rachlin et al. 1986). In the
delayed reward paradigm and the paradigm used by
McDonald et al. (2003), subjects could only win and not
lose reward (food or money, respectively), whereas only the
magnitude of the reward depended upon choice. It is
therefore possible, that these procedural and conceptual
differences explain the discrepancy in findings, and further-
more, that delay aversion and risk-taking processes are
differentially regulated by the (endo)cannabinoid system.
While response inhibition has been shown to be
impaired in human volunteers after THC administration
(McDonald et al. 2003), neither disruption of endocanna-
binoid signaling nor administration of a CB1 receptor
agonist had clear observable behavioral effects on stop-
signal task performance. In agreement with the assumption
of a “race model” between “go” and “stop” processes
(Logan 1994) and previous stop-signal data in rats (Eagle
and Robbins 2003a, b), the probability of successfully
inhibiting a response during a stop trial decreased in rats
when the onset of the stop signal was delayed in time.
Although SR141716A did not shift this inhibition curve as
a function of increasing stop-signal delays, the low dose
WIN55,212-2 (0.3 mg/kg) significantly deteriorated the
ability to inhibit responding with increasing stop-signal
delays. However, the primary parameter in this paradigm,
the average estimated stop-signal reaction time, or simply
put, speed of stopping, was not changed by any dose of
SR141716A or WIN55,212-2. In addition, median split
analyses revealed no differential drug effects in individuals
with “slow” vs “fast” stopping abilities as has been reported
previously for the effects of D-amphetamine on stopping
speed in both rats and humans (De Wit et al. 2002; Feola et
al. 2000). Collectively, our findings suggest that response
inhibition processes, as measured in the stop-signal para-
digm, are not under control of CB1 receptors. In the present
study, the speed of stopping was estimated from separate
SSRTs obtained from three stop-signal delays (200, 100,
and 50 ms before mean go RT), and consistent with this
estimation method, there was some variability in the SSRTs
depending on the delay (Band et al. 2003; Logan 1994),
with shorter stop-signal delays resulting in SSRTs of
approximately 140 ms and longer delays resulting in SSRTs
of approximately 300 ms. However, the variability in
SSRTs over delays was similar across all doses of both
drugs (data not shown), thus, ruling out the possibility that
this variability may have masked effects of SR141716A or
WIN55,212-2 on response inhibition. In contrast to the
measures of response inhibition, reaction times during
performance on go trials were slowed by both compounds
in line with their effects in the 5-CSRTT. With regard to
these effects of SR141716A, in the absence of changes on
omission errors in both the 5-CSRTT and the stop signal
paradigm, they cannot be solely interpreted in terms of
motor effects. Rather, the minor but significant increase in
response latencies of approximately 30 ms in both
paradigms (Table 1 and Fig. 4b) may indicate changes in
information processing speed induced by blockade of
endocannabinoid signaling. However, this notion is not
confirmed by previous sensorimotor gating data (Mansbach
et al. 1996; Martin et al. 2003). In contrast, the effects of
1.0 and 3.0 mg/kg WIN55,212-2 on reaction times in the
stop-signal paradigm may in part be secondary to changes
in locomotor activity, as these doses also increased the
number of omissions in the 5-CSRTT.
Remarkably, although both the stop-signal paradigm and
5-CSRTT measure aspects of impulsive action, only
inhibitory control in the 5-CSRTT was improved by
SR141716A. Impulsive action in the latter paradigm is
mainly measured as the inability to inhibit inappropriate
(premature) responses, whereas in the stop-signal paradigm
impulsive action is reflected in the inability to inhibit
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ongoing behavior, i.e., the inability to stop a behavioral
response that has just been initiated. Our observations
support the notion of different and separable forms of
inhibitory control, and moreover, suggest a differential role
for the endocannabinoid system therein. Likewise, lesion
studies have suggested that different brain regions are
involved in inhibitory control measured in either the 5-
CSRTT or stop-signal paradigm, as for instance, lesions of
the nucleus accumbens or subregions of the medial prefrontal
cortex have been shown to impair inhibitory control in the 5-
CSRTT (Christakou et al. 2004; Chudasama et al. 2003; Muir
et al. 1996) and not in the stop-signal paradigm (Eagle and
Robbins 2003b).
In summary, the present study provides evidence for a
differential involvement of the endocannabinoid system in
independent measures of impulsivity, as SR141716A
primarily affected inhibitory control, and neither impulsive
choice nor response inhibition, whereas WIN55,212-2 only
slightly affected response inhibition. In this regard, the
present data add to existing clinical and preclinical evidence
demonstrating that distinct measures of impulsivity can be
dissociated at a pharmacological and neuroanatomical level
(e.g., Chudasama et al. 2003; De Wit et al. 2002; McDonald
et al. 2003; Winstanley et al. 2004). Our findings may be of
particular interest with respect to the heterogeneity observed
in attention-deficit/hyperactivity disorder (Sonuga-Barke
2002) and suggest that possible novel pharmacotherapies
targeted at the cannabinoid system may benefit the subtype
resulting from poor inhibitory control, but not the motiva-
tional style, or delay aversion, subtype.
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